A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia (CONNEX-1)
Latest Information Update: 25 Jul 2024
At a glance
- Drugs Iclepertin (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Acronyms CONNEX-1
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim GmbH International; Boehringer Ingelheim Pharma KG
- 30 Jun 2024 This study has been Completed in Germany, According to European Clinical Trials Database record.
- 22 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 19 Feb 2024 Planned End Date changed from 31 Oct 2024 to 11 Oct 2024.